FOLLOWUS
Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road
- Chinese Journal of Integrative Medicine Vol. 24, Issue 9, Pages: 713-720(2018)
- Affiliations：
1. Department of Hepatology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University,Beijing,China
2. College of Traditional Chinese Medicine Affiliated to Capital Medical University,Beijing,China
3. Department of Good Clinical Practice, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University,Beijing,China
4. Department of Hepatology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences,Beijing,China
5. Department of Gastroenterology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences,Beijing,China
6. Department of Oncology, Guang’anmen Hospital of China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：Supported by National Natural Science Foundation Project (No. 81573767), Doctoral Innovation Fund from Chin Academy of Chinese Medical Sciences (No. CX201404)
DOI：10.1007/s11655-018-3007-1
CLC：Published：2018，
Published Online：25 June 2018，
Scan for full text
Wang, Js., Zhang, Qy., Cheng, Jl. et al. Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road., Chin. J. Integr. Med. 24, 713–720 (2018). https://doi.org/10.1007/s11655-018-3007-1
Jing-si Wang, Qiu-yun Zhang, Jin-lian Cheng, et al. Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road. [J]. Chinese Journal of Integrative Medicine 24(9):713-720(2018)
Wang, Js., Zhang, Qy., Cheng, Jl. et al. Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road., Chin. J. Integr. Med. 24, 713–720 (2018). https://doi.org/10.1007/s11655-018-3007-1 DOI：
Jing-si Wang, Qiu-yun Zhang, Jin-lian Cheng, et al. Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road. [J]. Chinese Journal of Integrative Medicine 24(9):713-720(2018) DOI： 10.1007/s11655-018-3007-1.
摘要
Hepatic fibrosis is a common feature of almost all chronic liver diseases. Formation of new vessels (angiogenesis) is a process strictly related to the progressive fibrogenesis which leads to cirrhosis and liver cancer. This review mainly concerns the relationship between angiogenesis and hepatic fibrosis
by considering the mechanism of angiogenesis
cells in angiogenesis
anti-angiogenic and Chinese medicine therapies.
Abstract
Hepatic fibrosis is a common feature of almost all chronic liver diseases. Formation of new vessels (angiogenesis) is a process strictly related to the progressive fibrogenesis which leads to cirrhosis and liver cancer. This review mainly concerns the relationship between angiogenesis and hepatic fibrosis
by considering the mechanism of angiogenesis
cells in angiogenesis
anti-angiogenic and Chinese medicine therapies.
关键词
angiogenesisHepatic FibrosisreviewChinese Medicine
Keywords
angiogenesisHepatic FibrosisreviewChinese Medicine
references
Sakat K, Ed S, Lee E, et al. Neovessel formation promotes liver fibrosis via providing latent transforming growth factor–β. Biochem Biophys Res Commun 2014;443:950–956.
Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887–1901.
Coulon S, Heindryckx F, Geerts A, et al. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;1478–3223.
Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol 2009;50:604–620.
Pereira ER, Liao N, Neale GA, et al. Transcriptional and posttranscriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One 2010;5:e12521.
Valfrè di Bonzo L, Novo E, Cannito S, et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009;24:1323–1341.
Raskopf E, Carmona MAG, van Cayzeele CJ, et al. Toxic damage increases angiogenesis and metastasis in fibrotic livers via PECAM–1. Biomed Res Int 2014;2014:712893.
Hsu SJ, Wang SS, Hsin IF, et al. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci (Lond) 2014;126:633–644.
Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–660.
Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932–936.
Yang L, Kwon J, Popov Y, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice, Gastroenterology 2014;146:1339–1350.
Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.
Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2–mediated sensitization and inflammation in the lung. Nature Med 2004;10:1095–1093.
Sahin H, Borkham–Kamphorst E, Kuppe C, et al. Chemokine Cxcl9 attenuates liver fibrosis associated angiogenesis in mice. Hepatology 2012;55:1610–1619.
Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003;52:1347–1354.
Kajdaniuk D, Marek B, Borgiel–Marek H, et al. Vascular endothelial growth factor (VEGF)–part 1: in physiology and pathophysiology. Endokrynol Pol 2011;62:444–455.
Salcedo X, Medina J, Sanz–Cameno P, et al. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005;22:23–30.
Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF–E (NZ–7 VEGF), preferentialy utilizes KDR/Flk–1 receptor and carries a potent mitotic activity without heparin–binding domain. J Biol Chem 1998;273:31273–31282.
Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol 2001;280:C1358–C1366.
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389–395.
Fernandez M, Mejias M, Garcia–Pras E, et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet–derived growth factor blockade in rats. Hepatology 2007;46:1208–1217.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
Lin HC, Huang YT, Yang YY, et al. Beneficial effects of dual VEGFR/FGFR inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. J Gastroenterol Hepatol 2014;29:1073–1082.
Kaur S, Tripathi D, Dongre K, et al. Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J Hepatol 2012;57:1193–1198.
Bueno M, Salgado S, Beas–arate C, et al. Urokinase–type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down–regulation and up–regulation of MMPs, HGF and VEGF. J Gene Med 2006;8:1291–1299.
Franchitto A, Onori P, Renzi A, et al. Expression of vascular endothelial growth factors and their receptors by hepatic progenitor cells in human liver diseases. Hepatobi Surg Nutr 2013;2:68–77.
Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia–dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942–1953.
Andrae J, Gallini R, Betsholtz C. Role of platelet–derived growth factors in physiology and medicine. Genes Dev 2008;22:1276–1312.
Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79–F113.
Bergsten E, Uutela M, Li X, et al. PDGF–D is a specific, proteaseactivated ligand for the PDGF beta–receptor. Nat Cell Biol 2001;3:512–516.
Donovan J, Abraham DA, Norman J. Platelet–derived growth factor signalling in mesenchymal cells. Front Biosci (Landmark Ed). 2013;18:106–119.
Donovan J, Xu SW, Norman J, et al. Platelet–derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 2013;6:9–10.
Fang L, Zhan SX, Huang C, et al. TRPM7 channel regulates PDGFBB–induced proliferation of hepatic stellate cells via PI3K and ERK pathways. Toxicol Appl Pharmacol 2013;272:713–725.
Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyteinteractions. Circ Res 2005;97:512–523.
Semela D, Das A, Langer D, et al. Platelet–derived growth factor signaling through Ephrin–B2 regulates hepatic vascular structure and function. Gastroenterology 2008;135:671–679.
McKeehan WL, Wang F, Kan M. The heparan sulfate–fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998;59:135–176.
Cheng AL, Shen YC, Zhu AX. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology 2011;81:372–380.
Lin HC, Huang YT, Yang YY, et al. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. J Gastroenterol Hepatol 2014;29;1073–1082.
Nakamura I, Zakharia K, Banini BA, et al. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS One 2015;10:e 0142355.
Klein S, Roghani M, Rifkin DB. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 1997;79:159–192.
Sleeman M, Fraser J, McDonald M, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001;271:171–182.
Semenza GL. Hypoxia–inducible factors in physiology and medicine. Cell 2012;148:399–408.
Qu A, Taylor M, Xue X, et al. Hypoxia–inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 2011;54:472–483.
Cannito S, Paternostro C, Busletta C, et al. Hypoxia, hypoxiainducible factors and fibrogenesis in chronic liver diseases. Histol Histopathol 2014 Jan;29:33–44.
Fraisl P, Mazzone M, Schmidt T, et al. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009;16:167–179.
Copple BL, Bai S, Burgoon LD, et al. Hypoxia–inducible factor–1 gulates the expression of genes in hypoxic hepatic stellate cells are important for collagen deposition and angiogenesis. Liver Int 2011;31:230–244.
Ueda N, Chihara D, Kohno A, et al. Predictive value of circulating angiopoietin–2 for endothelial damage related complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20;1335–1340.
Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double–edged sword? J Clin Oncol 2012;30:441–444.
Scholz A, Lang V, Henschler R, et al. Angiopoietin–2 promotes myeloid cell infiltration in a beta(2)–integrin–dependent manner. Blood 2011;118:5050–5059.
Hernández–Bartolomé A, Lopez–Rodríguez R, Rodríguez–Muñ oz Y, et al. Angiopoietin–2 serum levels Improve noninvasive fibrosis staging in chronic hepatitis C: a fibrogenic–angiogenic link. PLoS One 2013;8:e66143.
Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 2012;6:67–80.
Zhang F, Kong D, Chen L, et al. Peroxisome proliferatoractivated receptor–cinterrupts angiogenic signal transduction by transrepression of platelet–derived growth factor–breceptor in hepatic stellate cells. J Cell Sci 2014;127:305–314.
Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Rec Res Cancer Res 2010;180:103–114.
Medina J, Arroyo AG, Sanchez–Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185–1195.
Majumder S, Piguet AC, Dufour JF, et al. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol 2013;705:86–95.
Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008;135:1729–1738.
Witek RP, Yang L, Liu RS, et al. Liver cell–derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009;136:320–330.
Kaur S, Tripathi D, Dongre K, et al. Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J Hepatol 2012;57:1193–1198.
Yang L, Yue S, Yang L, et al. Sphingosine kinase/sphingosine 1–phosphate (S1P)/S1P receptor axis is involved in liver fibrosisassociated angiogenesis. J Hepatol 2013;59:114–123.
Corpechot C, Barbu V, Wendum D, et al. Hypoxia–induced VEGF and collagen expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002;35:1010–1021.
Lee JS, Semela D, Iredale J, et al. Sinusoidal remodeling and angiogenesis:a new function for the liver–specific pericyte? Hepatology 2007;45:817–825.
Paternostro C, David E, Novo E, et al. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010;16:281–288.
Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007;170:1942–1953.
Aleffi S, Petrai I, Bertolani C, et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005;42:1339–1348.
Winwood PJ, Arthur MJ. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin Liver Dis 1993;13:50–59.
Su LJ, Chang CC, Yang CH, et al. Graptopetalum paraguayense ameliorates chemical–Induced rat hepatic fibrosis in vivo and inactivates stellate cells and kupffer cells in vitro. PLoS One 2013;8:e53988.
Boltjes A, Movita D, Boonstra A, et al. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol 2014;61:660–671.
Horie Y, Wolf R, Russell J, et al. Role of Kupffer cells in gut ischemia/reperfusion–induced hepatic microvascular dysfunction in mice. Hepatology 1997;26:1499–505.
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014;20:7312–7324.
Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediat Inflamm 2012;2012:949157.
Marra F, Tacke F. Reviews in basic and clinical gastroenterology and hepatology. Gastroenterology 2014;147:577–594.
Franceschini B, Ceva–Grimaldi G, Russo C, et al. The complex functions of mast cells in chronic human liver diseases. Dig Dis Sci 2006;51:2248–2256.
Franceschini B, Russo C, Dioguardi N, et al. Increased liver mast cell recruitment in patients with chronic C virus–related hepatitis and histologically documented steatosis. J Viral Hepatiti 2007;14:549–555.
Shen DZ. A target role for mast cell in the prevention and therapy of hepatic fibrosis. Med Hypothes 2008;70:760–764.
Makhlouf HR, Ishak KG. Sclerosed hemangioma and sclerosing cavernous hemangioma of the liver: a comparative clinicopathologic and immunohistochemical study with emphasis on the role of mast cells in their histogenesis. Liver 2002;22:7–78.
Cogger VC, Mitchell SJ, Warren A, et al. Age–related loss of responsiveness to 2,5–dimethoxy–4–Iodoamphetamine in liver sinusoidal endothelial cells. J Gerontol A Biol Sci Med Sci 2014;69:514–518.
DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 2015;61:1740–1746.
Xie G, Wang X, Wang L, et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 2012;142:918–927.
Hu JH, Srivastava K, Wieland M, et al. Endothelial cell–derived angiopoietin–2 controls liver regeneration as a spatiotemporal rheostat. Science 2014;343:416–419.
Su TH, KaoI JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis–related liver fibrosis. Int J Mol Sci 2014;15:10578–10604.
Zhang ZL, Zhang F, Luan Y, et al. The update on implications and mechanisms of angiogenesis in liver fibrosis. Hepatol Res 2015;45:162–178.
Taura K, De Minicis S, Seki E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008;135:1729–1738.
Tugues S, Fernandez–Varo G, Munoz–Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919–1926.
Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatology 2010:53:976–980.
Thabut D, Routray C, Lomberk G, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenibin liver fibrosis. Hepatology 2011;54:573–585.
Yao Q, Lin Y, Li X, et al. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachlorideinduced rat liver fibrosis. Toxicol Lett 2013;222:72–82.
Zhang F, Zhang Z, Chen L, et al. Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells. J Cell Mol Med 2014;18:1392–1406.
Copple BL, Bai S, Burgoon LD, et al. Hypoxia–inducible factor–1α regulates expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int 2011;31:230–244.
Huang Y, Feng H, Kan T, et al. Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS One 2013;8:e73492.
Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003;52:1347–1354.
Wang YQ, Ikeda K, Ikebe T, et al. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP–470 in rats. Hepatology 2000;32:980–989.
Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998;97:381–390.
Engelse MA, Hanemaaijer R, Koolwijk P, et al. The fibrinolytic sistem and matrix metalloproteinases in angiogenesis and tumor progression. Semin Thromb Hemost 2004;30:71–81.
Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor–induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111–1120.
Liu YQ, Wang Z, Wang JN, et al. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor–b and vascular endothelial growth factor signalling. Liver Int 2013;33:504–515.
Fernandez M, Mejias M, Garcia–Pras E, et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet–derived growth factor blockade in rats. Hepatology 2007;46:1208–1217.
Jiao JJ, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009;25:223–229.
Neef M, Ledermann M, Saegesser H, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006;44:167–175.
Patsenker E, Popov Y, Stickel F, et al. Pharmacological inhibition of integrin α vβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009;50:1501–1511.
Yao QY, Lin YZ, Li X, et al. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride–induced rat liver fibrosis. Toxicol Lett 2013;222:72–82.
HSU SJ, Wang SS, I–Fang HSIN, et al. Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci 2014;126:633–644.
Peng Y, Tao Y, Wang Q, et al. Ergosterol is the active compound of cultured mycelium cordyceps sinensis on antiliver fibrosis. Evid Based Complement Alternat Med 2014;2014:537234.
Liu CH, Hu YY, Xu LM, et al. Effect of Fuzheng Huayu Formula and its actions against liver fibrosis. Chin Med (Chin) 2009;4:12.
Qu JH, Yu ZJ, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials 2014;15:438.
Zhao XK, Cheng ML, Wu RM, et al. Effect of Danshao Huaxian Capsule on gremlin and bone morphogenetic protein–7 expression in hepatic fibrosis in rats. World J Gastroenterol 2014;20:14875–14883.
Zhou YN, Sun MY, Mu YP, et al. Xuefuzhuyu Decoction inhibition of angiogenesis attenuates liver fibrosis induced by CCl4 in mice. J Ethnopharmacol 2014;153:659–666.
Chen JY, Chen HL, Cheng JC, et al. A Chinese herbal medicine, Gexia–Zhuyu Tang (GZT), prevents dimethylnitrosamine–induced liver fibrosis through inhibition of hepatic stellate cells proliferation. J Ethnopharmacol 2012;142:811–818.
Liang XL, Yuan JY. Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B–ultrasound. Asian Pacific J Tropical Med 2013;6:658–662.
Shen X, Cheng SS, Peng Y, et al. Attenuation of early liver fibrosis by herbal compound "Diwu Yanggan" through modulating the balance between pithelial–to–mesenchymal transition and mesenchymal–toepithelial transition. BMC Complement Alternat Med 2014;14:418.
Zhou YX, Chen J, Li JP, et al. Chinese medicinal herbs In treating model rats with hepatic fibrosis. Afr J Tradit Complement Altern Med 2009;7:104–108.
Lin HJ, Tseng CP, Lin CF, et al. A Chinese herbal decoction, modified Yi Guan Jian, Induces apoptosis in hepatic stellate cells through an ROS–mediated mitochondrial/Caspase pathway. Evid Based Complement Alternat Med 2011;2011:459531.
Xi SY, Yue LF, Shi MM, et al. The effects of Taoren–Honghua herb pair on pathological microvessel and angiogenesis–associated signaling pathway in mice model of CCl4–induced chronic liver disease. Evid Based Compl Alterna Med 2016;2016:2974256.
0
Views
0
Downloads
1
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
